Neuphoria Therapeutics (NEUP) FCF Margin (2024 - 2025)

Neuphoria Therapeutics (NEUP) posted quarterly FCF Margin of 26850.85% for Q2 2025, up 35065.18% quarter-over-quarter from 76.36% in Q1 2025.

Neuphoria Therapeutics (NEUP) FCF Margin (2024 - 2025) Analysis & Trends

Neuphoria Therapeutics (NEUP) has reported FCF Margin for 2 consecutive years, with 26850.85% the latest figure, recorded in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Vertex Pharmaceuticals	138.83 Bn	130.98 Bn	2.84 Bn	30.39%
2	Regeneron Pharmaceuticals	85.79 Bn	77.79 Bn	3.93 Bn	13.35%
3	Argenx Se	64.95 Bn	59.77 Bn	1.37 Bn	-
4	Moderna	58.59 Bn	53.46 Bn	52.00 Mn	-388.28%
5	BeOne Medicines	41.93 Bn	36.83 Bn	1.53 Bn	25.68%
6	Alnylam Pharmaceuticals	31.52 Bn	28.21 Bn	992.69 Mn	22.62%
7	BioNTech SE	27.98 Bn	9.58 Bn	668.28 Mn	41.07%
8	Insmed	27.42 Bn	26.26 Bn	358.27 Mn	-22.35%
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	70.82%
10	Neuphoria Therapeutics	21.37 Mn	1.93 Mn	-	-

Download Data